ArticleBreast cancer (Tokyo, Japan)2021

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.

Ryohei Ogata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.